The FDA Just Admitted It Can't Regulate Medicine the Old Way Anymore
Written by the Global Wellness Hub Editorial Team · Reviewed for accuracy For decades, a new drug's path to your pharmacy shelf followed a predictable script: years of lab work, animal testing, three phases of human trials, then a mountain of paperwork reviewed by human regulators. That script just got rewritten, not by a pharmaceutical company, but by the regulators themselves. On January 14, 2026, the FDA and its European counterpart, the EMA, published something that had never existed before: a joint set of ten guiding principles for how artificial intelligence should be built, used, and monitored across the entire lifecycle of a drug. This is the first time these two agencies have aligned on AI rules for medicine at all, and it tells you how fast this shift is actually moving. Where AI has already changed the research itself The clearest evidence isn't a prediction. It's already in the numbers. An internal FDA audit from November 2025 found that 60 percent of New Dru...